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Background and purpose: Heat shock Protein 90 (Hsp90) is a molecular chaperone that folds, stabilizes, and
functionally regulates many cellular proteins involved in oncogenic signaling and in the regulation of
radiosensitivity. It is upregulated in response to stress such a heat. Hyperthermia is a potent radiosensitizer, but
induction of Hsp90 may potentially limit its efficacy. Our aim was to investigate whether the new Hsp90 inhibitor
NVP-HSP990 increases radiosensitivity, thermosensitivity and radiothermosensitivity of human tumor cell lines.
Material and methods: U251 glioblastoma and MIA PaCa-2 pancreatic carcinoma cells were used. To determine
clonogenic survival, colony forming assays were performed. Cell viability and proliferation were assesed by Trypan
blue staining. Cell cycle and apoptosis analyses were performed by flow cytometry. DAPI staining was used to
detect mitotic catastrophe.
Results: NVP-HSP990 increased the thermosensitivity, radiosensitivity and radio-thermosensitivity of both cell lines
in clonogenic assays. 72 hours after irradiation with 4 Gy, a significant reduction in cell number associated with
considerable G2/M acumulation and mitotic catastrophe as well as cell death by apoptosis/necrosis was observed.
Conclusions: Treatment with NVP-HSP990 strongly sensitized U251 and MIA PaCa-2 cells to hyperthermia and
ionizing radiation or combination thereof through augmentation of G2/M arrest, mitotic catastrophe and associated
apoptosis.
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Heat shock protein 90 (Hsp90) is an evolutionary con-
served molecular chaperone which under physiological
conditions participates in protein folding, intracellular
transport, maintenance and degradation of proteins. Pro-
teins, which are activated and stabilized by Hsp90, are
referred to as “clients”. A lot of them are crucial for con-
stitutive cell signaling and adaptive responses to stress
[1]. Hsp90 is expressed at 2–10-fold higher levels in tu-
mor tissue than in normal tissue [2]. Its most important
function is to protect mutated and overexpressed* Correspondence: dusan.milanovic@uniklinik-freiburg.de
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reproduction in any medium, provided the oroncoproteins from misfolding and degradation. It has
been recognized to be essential for the stability and
function of a wide variety of kinases such as EGFR, Erb-
B2, Akt, BCR-ABL, VEGFR2 involved in cell cycle
regulation, survival and oncogenic signaling [3]. These
proteins play also critical roles in the regulation of radio-
sensitivity [4-6]. Thus, the inhibition of Hsp90 may rep-
resent an attractive therapeutic strategy not only
reducing basal survival of tumor cells but also increasing
their radiosensitivity.
Heat is a very potent radiosensitizer in vitro and
in vivo [7,8]. Clinical studies have shown that the combi-
nation of conventional radiation therapy with hyperther-
mia leads to significantly better tumor control [9].
Hsp90 is heat-inducible in normal and in tumor cellsral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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effects of ionizing radiation (IR) via activation of “client
proteins” which may contribute to radioresistance as
mentioned above. Theoretically, small molecules desig-
ned to inhibit Hsp90 might increase the effect of hyper-
thermia followed by enhanced radiosensitivity.
NVP-HSP990 is a novel, highly potent orally available
2-aminothienopyrimidine class, non-geldanamycin based
Hsp90 inhibitor [11]. It has been shown that treatment
of established cell lines from different tumor entities
with the non-geldanamycin based Hsp90 inhibitors
NVP-BEP800 and NVP-AUY922 increase their sensitiv-
ity towards IR [12].
Glioblastoma multiforme and pancreatic carcinoma
represent tumors which are resistant to conventional
radiochemotherapeutical regimes and despite intensive
research and development of new targeted therapies
prognosis of patients with these tumors remains poor
[13,14], indicating the need for new therapeutic
approaches.
Here we investigated whether treatment with the
Hsp90 inhibitor NVP-HSP990 and hyperthermia en-
hance thermal sensitivity and consequently radiosensitiv-
ity of U251 glioma and MIA PaCa-2 pancreatic
carcinoma cells.Materials and methods
Cell culture and reagents
The U251 human glioblastoma and pancreatic carci-
noma MIA PaCa-2 cell line were obtained from the tu-
mor bank of the National Cancer Institute (NCI),
Frederick, Maryland. Cells were grown as a monolayer
in RPMI-1640 culture medium supplemented with 10%
foetal bovine serum (FBS; Biochrom, Berlin, Germany)
at 37°C under 8.5% CO2. NVP-HSP990 was kindly pro-
vided by Novartis Institutes for Biomedical Research
(Basel, Switzerland). The drug was dissolved in DMSO
and stock solutions were stored at −20°C.Hyperthermia
Hyperthermia was provided by a cell incubator (Heraeus,
type Heracell), reaching temperatures of up to ~55°C with
a precision of 0.1°C. The temperature of 37°C was chosen
as control. Before starting a hyperthermia, the tempe-
rature was controlled with 3 thermocouples from the
interstitial hyperthermia device (Academic Ziekenhuis
Utrecht, The Netherlands), which were inserted in needles
and placed in the cell culture flasks filled with 5 ml culture
media. Each thermocouple has 7 different points from
which the temperature was measured. When the aver-
age temperature value in the incubator reached 42°C,
the cells were incubated for 1 hour and afterwards
replaced to 37°C.Hyperthermia and drug treatment
To investigate the effect of NVP-HSP990 on colony for-
mation as a sole compound, cells were treated with in-
creasing drug concentrations (0.01, 0.02, 0.05 and
0.1 μM). In combination treatment with hyperthermia,
the cells were treated with the same drug concentra-
tions. Immediately after adding the drug, the cells were
incubated for 1 hour at 42°C and afterwards replaced to
37°C. 24 hours later, the cells were trypsinised and 100
cells were plated for colony forming assay (CFA) without
drug using 25 cm2 tissue flasks (Falcon Becton-
Dickinson, Germany).
γ-irradiation
Irradiation was performed at room temperature using a
Gammacell 40 137Cs laboratory irradiator. After irradia-
tion, the cells were recovered in growth medium for 24 -
hours until harvest.
Combined treatment with NVP-HSP990, hyperthemia and IR
200.000 U251 cells were seeded in 25 cm2 tissue culture
flasks and 24 hours later treated with 0.02 or 0.1 μM
NVP-HSP990. Control cells were treated in parallel with
respective concentrations of DMSO as a vehicle control.
24 hours after start of treatment with NVP-HSP990, the
cells were trypsinised and plated for CFA without drug.
In experiments, where hyperthermia was used, the cells
were treated with 0.05 μM NVP-HSP990. Immediately
after adding the drug, cells were icubated at 42°C for
1 hour and afterwards replaced to 37°C. Figure 1 shows
the treatment schedule for these experiments.
Colony forming assay (CFA)
After allowing the cells to attach to the petri dish, the
cells were irradiated with 0, 2, 4, 6 or 8 Gy without
NVP-HSP990. 12 days after seeding, the colonies were
fixed with methanol/acetic acid (3:1) and stained with
crystal violet dye (1%). The number of colonies contain-
ing at least 50 cells was determined, and the surviving
fractions were calculated. The curves were normalised
to SF1 (100% cell survival). The surviving fractions were
calculated using the plating efficiency for each treatment
group (42°C, NVP-HSP990 or 42°C + NVP-HSP990
combination). Plating efficiency and surviving fractions
were determined for each cell line and treatment. Cell
survival curves were fitted by the linear-quadratic model
SF = exp[−(αD + βD2)].
Assessment of cell proliferation and viability by Trypan
blue exclusion and FACS analysis
To determine the number of viable cells, trypan blue
exclusion tests were conducted. To assess induction of ap-
optosis and global cell death, annexin-V and propidium-


















Figure 1 Schematic diagram illustrating the treatment schedule for cell survival experiments.
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U251 and MIA PaCa-2 cells were treated with 0.05 μMNVP-
HSP990. Immediately after adding the drug, the cells were in-
cubated for 1 hour at 42°C and then replaced to 37°C. 24 hours
later, the growth medium was replaced and the cells were irra-
diated with a single dose of 4 Gy. 24 and 72 hours later, the
cells were stained with annexin V-FITC and PI and analyzed
by FACS (FMT 500) from Beckman Coulter.
Cell cycle analyses
Exponentially growing U251 and MIA PaCa-2 cells were
treated and fixed 8, 24 and 48 hours later with 70% etha-
nol. After storage at −20°C overnight, the cells were
washed and incubated with PI (50 μg/mL) and RNase
(100 μg/mL) for 2 h at 4°C. After washing, the cells were
analyzed for DNA content by flow cytometry.
Assessment of mitotic catastrophe
U251 cells were treated as described. 3 or 5 days later, the
cells were fixed, stained with 4'-6-diamidino-2-phenylindole
(DAPI) and analysed under an Olympus BX41 fluorescenceA
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Figure 2 Colony forming assay after exposure of U251 (A) or MIA PaC
at 37°C (black bars) or in combination with hyperthermia (grey bars).
against non-treated controls (DMSO). Colonies containing at least 50 cells w
each performed in triplicate. The results were considered to be statistically
drug only”-#).microscope equipped with a digital camera CC-12 soft imag-
ing system (U-CMAD3, Olympus). For each assessment of
the extent of mitotic catastrophe, 200 nuclei were examined.
Statistical analyses
The Mann–Whitney U Test and Kruskal-Wallis analysis
of variance were used to compare quantification data.
Statistical analysis was conducted with Statistical Pack-
age for Social Sciences software (SPSS Inc.). We used a
2-sided test with significance level of 0.05 for all statisti-
cal analyses. Synergy was calculated by the fractional
product method that allows an evaluation of synergy at a
defined level of effect [15].
Results
The effect of hyperthermia and NVP-HSP990 on
clonogenic survival of U251 and MIA PaCa-2 cells
Treatment with 0.01 or 0.02 μM NVP-HSP990 (Figure 2A
and 2B) did not influence colony formation while the treat-
ment with 0.05 μM NVP-HSP990 slightly but significantly
reduced colony numbers in both cells lines comparedB
NVP-HSP990 [µM]












a-2 (B) cell lines to different concentrations of NVP-HSP990 alone
Triplicate data from two experiments were averaged and normalised
ere scored. All data are obtained from 3 independent experiments,
significant when P < 0.05 (“comparison to control”-*, “comparison to
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p = 0.042). Similar results were observed if cells were
treated with 0.1 μM NVP-HSP990. Sole heat treatment
caused modest but also significant reduction of colony
number in both cell lines (U251 p = 0.003, MIA PaCa-2
p = 0.042). The treatment of U251 cells with 0.05 μM
NVP-HSP990 at 42°C markedly reduced colony numbers
compared to either treatment alone (NVP-HSP990 vs. NVP-
HSP990 at 42°C p = 0.00034). Similar results were observed
if the cells were treated with 0.1 μM NVP-HSP990 at 42°C.
In case of MIA PaCa-2 cells, incubation at 42°C in the pres-
ence of 0.05 or 0.1 μM NVP-HSP990 caused significant
reduction of colony formation compared to treatment with
NVP-HSP990 alone (p = 0.00034 for both concentrations).
The effect of NVP-HSP990 on cellular radiosensitivity
assesed by CFA
The influence of NVP-HSP990 on the radiosensitivity of
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Figure 3 Influence of NVP-HSP990 and hyperthermia on the radiosen
incubated with 0.02 or 0.1 μM NVP-HSP990 for 24 h. Thereafter, growth me
cells were irradiated with single IR doses ranging between 2 and 8 Gy (C a
hyperthermia, U251 cells (C) or MIA PaCa-2 cells (D) were simultaneously tr
37°C for the next 23 hours and then irradiated as described above. Colony
containing at least 50 cells were scored. Data show mean values and rangeCFA. Based on the data shown in Figure 2A and 2B, the
cells were pretreated with 0.02 or 0.1 μM NVP-HSP990
for 24 h, then seeded as single cells and exposed to X-
ray doses up to 8 Gy. The radiosensitivity was deter-
mined by CFA. Pretreatment with 0.1 μM NVP-HSP990
markedly increased radiosensitivity of both U251
(Figure 3A) and MIA PaCa-2 (Figure 3B) cells at all dose
levels while pretreatment with 0.02 μM NVP-HSP990
did not change radisensitivity of both cell lines.
Combined treatment with NVP-HSP990 and hyperthermia
strongly increases the radiosensitivity of U251 and MIA
PaCa-2 cells
The influence of the combined treatment with NVP-
HSP990 and hyperthermia on the radiosensitivity of
both cell lines was also analysed by CFA. While treat-
ment with 0.05 μM NVP-HSP990 or heating with 42°C
for 1 hour had only a modest effect on radiosensitivity
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sitivity of U251 and MIA PaCa-2 cells (A and B). The cells were
dia containing NVP-HSP990 were replaced with fresh medium and the
nd D). In the case of the combined treatment with NVP-HSP990 and
eated with 0.05 μM NVP-HSP990 and 42°C for 1 hour, then replaced to
forming efficiency was determined 12 days later and colonies
of 2 independent experiments each plated in triplicate.
Milanović et al. Radiation Oncology 2013, 8:42 Page 5 of 9
http://www.ro-journal.com/content/8/1/42caused a potent radiosensitization. In case of irradiation
with 6 or 8 Gy, no colony formation was detected any-
more. Treatment of the MIA PaCa-2 cells (Figure 3D)
with 0.05 μM NVP-HSP990 had a more pronounced
radiosensitizing effect in comparison to U251 cells.
Heating of these cells caused further radiosensitization
at any irradiation dose. At a dose of 8 Gy, no colony for-
mation was observed anymore.
Effect of treatments on proliferation and apoptosis in
U251 and MIA PaCa-2 cells
Trypan blue exclusion staining showed that the stron-
gest reduction in viable cell numbers was indeed
achieved in the case of triple combinations (only 5% of
the cells survived compared to untreated controls) inA
Treatment



























































































































Figure 4 The effects of treatment with NVP-HSP990, hyperthermia an
and MIA PaCa-2 cells (D, E, F). In figure A and D black bars represent no
with a single dose of 4 Gy. The cells were treated with 0.05 μM NVP-HSP99
in the presence of the inhibitor. Thereafter the culture medium was replace
with a single dose of 4 Gy. 72 hours later, the cells were stained with trypa
SEM from 3 independent experiments is shown. To detect the percentage
anti-Annexin V antibody and propidium iodide (B, C, E, F). Black bars repre
2 independent experiments are shown.U251 (Figure 4A) and MIA PaCa-2 cells (Figure 4D)
(p = 0.04935 for both cell lines). All other treatments
also caused significant antiproliferative effects. MIA
PaCa-2 cells were more sensitive to treatment with
NVP-HSP990 alone compared to U251 cells. In the case
of U251 cells, the effects of the double combination of
NVP-HSP990 plus hyperthermia (calculated 43%, ob-
served 16% surviving cells) and the triple combination
including IR (calculated 4.1%, observed 3.64% surviving
cells) were synergistic or additive, respectively, compared
to the individual treatments (Figure 4A). In the case of
MIA PaCa-2 cells these combinations did not synergisti-
cally enhance the effect of NVP-HSP990 alone, which
was very strong. Analysis of annexin-V/PI -staining by
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d 4 Gy IR on cell proliferation and cell death of U251 (A, B, C)
n-irradiated cells while grey bars represent cells which were irradiated
0 and 42°C for 1 hour and then replaced to 37°C for the next 23 hours
d with fresh medium without inhibitor and the cells were irradiated
n blue to determine the number of viable cells (A, D). Mean value and
of apoptotic/necrotic cells, cells were stained with FITC-conjugated
sent apoptotic while grey bars necrotic cells. Mean values and range of
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not cause remarkable increase in the number of apopto-
tic/necrotic cells while combined treatment had a stron-
ger effect (Figure 4B). Irradiation with 4 Gy caused a
considerable increase in the number of apoptotic/ne-
crotic cells independently of the treatment (Figure 4B).
In the case of MIA PaCa-2 cells annexin-V/PI -staining
revealed that NVP-HSP990 alone caused a higher apo-
ptotic/necrotic percentage in comparison to U251 cells
and that additionally heating of these cells did not aug-
ment the effect of NVP-HSP990 (Figure 4E). The most
pronounced increase in numbers of apoptotic and dead
cells in MIA PaCa-2 cells was observed after treatment
with the triple combination (Figure 4F).
Cell cycle alterations in U251 and MIA PaCa-2 cells
Figure 5A shows that U251 cells which were heated with
42°C or treated with NVP-HSP990 did not show differ-
ences in the number of cells accumulating in the G2/M
phase. 8 hours after treatment with hyperthermia and
NVP-HSP990, increased numbers of cells accumulated
in G2/M. After 24 or 48 hours there was no difference
compared to untreated cells. 8 hours after irradiation
with 4 Gy (Figure 5B) an increased number of cells accu-
mulated in G2/M, while 48 hours after irradiation the
cell number dropped to the level of untreated cells. A
similar result was obtained when the cells were heatedA





































Figure 5 Effect of different treatments on G2/M arrest of U251 (A, B)
and treated with 0.05 μM NVP-HSP990 for 24 h as a sole modality (A, C) or
cells accumulating in G2/M is shown. Mean values and range of 2 indepenbefore irradiation. In the case of the triple combination,
maximal G2/M-arrest was reached only after 24 hours.
In MIA PaCa-2 cells only irradiation with 4 Gy caused
an increased number of cells accumulating in G2/M.
Effect on mitotic catastrophe in U251 cells
3 or 5 days after a 4 Gy irradiatiation, DAPI stainings
were performed and the morphology of the cells and
their nuclei were microscopically analysed (Figure 6A-
C). Hyperthermia or NVP-HSP990 inhibitor alone did
not significantly increase the percentage of cells with
signs of mitotic catastrophe (micro- or multinucleated
cells), whereas the double combination of the two
slightly increased it. In γ-irradiated cells, any additional
treatment caused an increase in the number of cells
undergoing mitotic catastrophe. The strongest increase
(ca. 60% of cells) was found in cultures treated with the
triple combination (p = 0.04935). Additive effects were
observed after 3 days and 5 days in double and triple
combinations (double combination after 5 days expected
9.9% fragmented cells, observed 11.33%, triple combi-
nation expected 34.5%, observed 50.16% fragmented
cells).
Discussion
The treatmant of patients with glioblastoma and pancre-
atic carcinoma remains a challenge. In the present study,B













and MIA PaCa-2 cells (C, D). The cells were heated for 1 h with 42°C
in combination with irradiation with 4 Gy (B, D). The percentage of
dent experiments are shown.
AB
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Figure 6 Effect of treatments on mitotic catastrophe (A). Representative image showing aberrant mitotic figures and increased numbers of
multinucleated and apoptotic cells observed in U251 cell culture treated with NVP-HSP990, hyperthermia and γ-IR. 72 hours or 120 hours after
γ-IR, DAPI was used to stain the DNA. Yellow arrowheads indicate multinucleated, white arrowheads apoptotic (with condensed DNA) and red
arrowheads cells with aberrant mitotic figures. Quantification was performed after 72 h (B) or 120 hours (C) after IR. 200 cells were counted per
sample. Mean value and SEM of 3 independent experiments are shown.
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tor NVP-HSP990 strongly sensitizes U251 glioma and
MIA PaCa-2 pancreatic carcinoma cells to hyperthermia
and IR and particulary to the combination thereof. The
triple combination caused a significant reduction in cell
number which was associated with a morphological al-
terations typical of mitotic catastrophe and apoptosis.
There is a lot of experimental [16-18] and clinical evi-
dence that hyperthermia can increase the effectiveness of
other conventional treatments such chemotherapy [19] or
especially radiotherapy [20,21]. The exact mechanism how
hyperthermia increases radiosensitivity is still not
completely elucidated but it has been proposed that hy-
perthermia may interfere with radiation-induced DNA
damage [22]. On the other hand, heat shock proteins me-
diate resistance to hyperthermia [23]. It has been shown
that inhibition of Hsp90 with geldanamycin causes de-
layed and impaired recovery from heat shock [24]. In
HEK293 cells, specific inhibition of Hsp90 together with
short term exposure (20–60 min) to 42°C was highly cyto-
toxic, through accelerated degradation of Cdc25A [25], a
member of the CDC25 family of phosphatases which
is specifically degraded in response to DNA damage
[26]. These findings support the hypothesis that theantineoplastic effect of hyperthermia could be potentiated
by concurrent inhibition of Hsp90. In our experimental
conditions, we observed that U251 and MIA PaCa-2 cells
which were incubated for 1 hour at 42°C and concurrently
treated with NVP-HSP990 showed a significantly lower
capability to form colonies in comparison to cells which
were treated with only one of the two modalities.
The effects of combined hyperthermia and irradiation
treatment depend on many different factors such a heat-
ing temperature, heating time, sequence and time inter-
val between the two modalities [27]. Despite intensive
research, it is still not clear wheather hyperthermia be-
fore or after irradiation causes a more pronounced en-
hancement of radiation damage. Probably, this effect is
cell-type specific. In the case of concurrent irradiation
and hyperthermia, maximal additive/synergistic effects
can be expected while increasing the intervals of time
between hyperthermia and IR, regardless of sequence,
will abrogate the radiosensitisation induced by hyper-
thermia [28]. As expected, because of the time interval
of 23 hours between hyperthermia and IR, we observed
only a weak influence of hyperthermia on radiosensitiv-
ity, cell cycle distribution, induction of mitotic catastro-
phe and apoptosis.
Milanović et al. Radiation Oncology 2013, 8:42 Page 8 of 9
http://www.ro-journal.com/content/8/1/42It has been proposed that the radiosensitising effect of
Hsp90 inhibitors is caused by degradation of several pro-
teins such a ErbB2, EGFR, Raf-1 and Akt [29,30] which re-
portedly can influence radioresistance. DNA repair and
cell cycle checkpoint activation are other proposed mech-
anisms by which Hsp90 can influence the DNA damage
response to IR [31]. A previous study reported that a
24 h-pretreatment with an Hsp 90 inhibitor similar to NVP
-HSP990, NVP-BEP800, caused an increase in radiosensitiv-
ity in two glioblastoma, one lung carcinoma and one fibro-
sarcoma cell line through cell-cycle impairment, increased
DNA damage and repair protraction [12]. The authors
found that changes in the expression of survival markers
(Hsp90, Hsp70, Akt, phospho-Akt, Raf-1 and survivin), an
apoptosis-associated protein (cleaved caspase 3) or of the
functional p53 status did not significantly contribute to the
sensitivity of two out of four tested cell lines to NVP-
BEP800 alone or in combination with IR. Another group
found that the geldanamycin-based Hsp90 inhibitor
17-dimethylaminoethylamino-17-demethoxygeldanamycin
(17-DMAG) enhances radiosensitization of human U251
and MIA PaCa-2 cells [31]. The treatment of the cells with
this compound caused a reduction of the expression of
Akt, Raf-1 and especially ErbB2. The authors further
reported that treatment of DU145 prostate carcinoma
cells with 17-DMAG abrogated the G2- and S-phase cell
cycle checkpoints and enhanced the radiosensitivity of the
cells.
It has been reported that treatment of the human lung
adenocarcinoma cell line A549 with KNK437, an benzy-
lidene lactam compound which acts as a heat shock
protein inhibitor, causes the enhancement of thermal
radiosensitization in mild hyperthermia combined with
low dose IR [32]. In the same study, it has been demon-
strated that KNK437 caused inhibition of Hsp72 and
Hsp27 expression. NVP-HSP990 shows a different
mechanism of action; it binds to the NH2-terminal
ATP-binding pocket of Hsp90 while KNK437 inhibits
synthesis of various heat shock proteins at the mRNA
level. KNK437 has also been proposed to induce radio-
resistance of A-172 human glioblastoma and human
squamous cell carcinoma cells [33].
In our experiments, we observed that pretreatment of
U251 cells with NVP-HSP990 and hyperthermia before
irradiation with 4 Gy caused a delayed acumulation of
cells in the G2/M phase. The strongest effect was
detected 24 hours after irradiation. Three to five days af-
ter the irradiation teatment, we observed a strong in-
crease of the number of cells with morphological signs
of mitotic catastrophe (micro- and multinucleated cells)
[34,35]. The number of apoptotic cells also increased. As
large numbers of necrotic cells (taking up PI) were not
found, this suggests that mitotic catastrophe constitutes
a prelude to apoptotic cell death. Similar findings werereported for a novel small molecule inhibitor that lowers
the threshold for Hsf1 (Heat shock factor protein 1) acti-
vation [36]. The inhibition enhanced thermal sensitivity
and significant thermal radiosensitization followed by
loss of mitochondrial potential and mitotic catastrophe
in HT29 colon carcinoma cells.
Conclusion
Taken together, our study shows that NVP-HSP990, a
fully synthetic, orally available Hsp90 inhibitor exibits
strong anti-tumor effects on U251 human glioblastoma
and MIA PaCa-2 pancreatic carcinoma cells through an
increase of sensitivity towards heat and ionising irradia-
tion. Further preclinical studies are warranted to clarify
the complex mechanisms of its action and to explore the
therapeutic potential of this approach in vivo.
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